振东制药
(300158)
| 流通市值：78.37亿 | | | 总市值：78.41亿 |
| 流通股本：10.05亿 | | | 总股本：10.05亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,456,942,003.34 | 754,532,591.77 | 2,971,127,572.67 | 2,269,424,815.15 |
| 营业收入 | 1,456,942,003.34 | 754,532,591.77 | 2,971,127,572.67 | 2,269,424,815.15 |
| 二、营业总成本 | 1,459,772,217.38 | 759,035,483.8 | 3,381,880,603.7 | 2,295,486,580.37 |
| 营业成本 | 711,756,735.99 | 384,133,474.79 | 1,560,125,224.31 | 1,115,030,240.58 |
| 税金及附加 | 16,461,680.26 | 7,659,182.76 | 30,852,129.21 | 23,077,262.22 |
| 销售费用 | 517,269,057.71 | 255,368,911.03 | 1,139,456,991.36 | 837,111,655.22 |
| 管理费用 | 136,835,641.67 | 63,126,961.31 | 301,178,511.88 | 174,976,018.01 |
| 研发费用 | 77,443,275.28 | 48,435,492.5 | 351,477,781.37 | 146,074,950.49 |
| 财务费用 | 5,826.47 | 311,461.42 | -1,210,034.43 | -783,546.15 |
| 其中:利息费用 | 738,515.79 | 558,117.52 | 3,605,558.57 | 2,633,127.27 |
| 其中:利息收入 | 1,498,277.23 | 472,329.53 | 5,671,229.46 | 4,576,913.58 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,328,710.16 | 845,023.58 | -139,440,121.7 | 3,016,533.94 |
| 加:投资收益 | 6,519,141.08 | 3,416,186.8 | 41,972,827.58 | 34,278,947.85 |
| 资产处置收益 | 4,604.73 | 250 | 11,256,735.65 | 11,668,352.12 |
| 资产减值损失(新) | -8,947,402.13 | 7,358,017.91 | -294,073,445.53 | -8,693,163.56 |
| 信用减值损失(新) | -1,789,449.56 | -797,892.23 | 3,197,892.44 | -12,203,461.97 |
| 其他收益 | 32,254,346.79 | 6,176,852.62 | 73,132,495.15 | 55,051,982.34 |
| 四、营业利润 | 26,539,737.03 | 12,495,546.65 | -714,706,647.44 | 57,057,425.5 |
| 加:营业外收入 | 1,066,477.61 | 316,788.49 | 9,290,411.66 | 3,915,822.61 |
| 减:营业外支出 | 6,695,178.32 | 6,193,253.49 | 609,605,746.66 | 9,204,428.72 |
| 五、利润总额 | 20,911,036.32 | 6,619,081.65 | -1,315,021,982.44 | 51,768,819.39 |
| 减:所得税费用 | 14,407,439.16 | 5,613,313.22 | 17,917,113.01 | 15,203,804.72 |
| 六、净利润 | 6,503,597.16 | 1,005,768.43 | -1,332,939,095.45 | 36,565,014.67 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 6,503,597.16 | 1,005,768.43 | -1,332,939,095.45 | 36,565,014.67 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 7,931,302.93 | 1,157,176.86 | -1,328,563,928.26 | 40,123,303.12 |
| 少数股东损益 | -1,427,705.77 | -151,408.43 | -4,375,167.19 | -3,558,288.45 |
| 扣除非经常损益后的净利润 | -8,176,408.91 | 289,616.69 | -686,339,926.76 | -30,395,578.85 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | 0 | -1.3 | 0.04 |
| (二)稀释每股收益 | 0.01 | 0 | -1.3 | 0.04 |
| 八、其他综合收益 | -1,147,236.17 | 652.32 | -47,070,237.62 | 304,241.41 |
| 归属于母公司股东的其他综合收益 | -1,147,236.17 | 652.32 | -47,070,237.62 | 304,241.41 |
| 九、综合收益总额 | 5,356,360.99 | 1,006,420.75 | -1,380,009,333.07 | 36,869,256.08 |
| 归属于母公司股东的综合收益总额 | 6,784,066.76 | 1,157,829.18 | -1,375,634,165.88 | 40,427,544.53 |
| 归属于少数股东的综合收益总额 | -1,427,705.77 | -151,408.43 | -4,375,167.19 | -3,558,288.45 |
| 公告日期 | 2025-08-25 | 2025-04-21 | 2025-04-21 | 2024-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |